Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast

Journal of the College of Physicians and Surgeons Pakistan

Volumn 15, Issue 4, 2005, Pages 225-229

  Aziz, Syed Abdul ^a   Pervez, Shahid ^a   Khan, Shaista M ^a   Kayani, Naila ^a   Nasir, Muhammad Israr ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Carcinoma breast; PCNA; Prognosis; Survival

Indexed keywords

CYCLINE;

ADULT; ARTICLE; AXILLARY LYMPH NODE; CANCER GRADING; CANCER INFILTRATION; CANCER MORTALITY; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; FOLLOW UP; HISTOPATHOLOGY; HOSPITAL DEPARTMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; METASTASIS; OUTCOMES RESEARCH; PAGET NIPPLE DISEASE; PAKISTAN; PATHOLOGY; POPULATION RESEARCH; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SAMPLING; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR VOLUME; UNIVERSITY HOSPITAL;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 18744408201     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Celis JE, Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S-phase. Proc Natl Acad Sci USA 1995; 82: 3262.
2. Mathews MB, Bernstein RM, Franza BR Jr., Garrelo JI. et al. Identity of the proliferating nuclear antigen and cyclin. Nature 1984; 309: 374-6.
3. Robbins BA, dela Vega D, Ogata K, Tan EM, Nakamunar RM. Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 1987; 111: 841-5.
4. Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978; 121: 2228-34.
5. Celis JE, Bravo R, Larsen PM, Fey SJ. Cyclin: a nuclear protein whose level correlates directly with the proliferative state of normal as well as transformed cells. Leuke Res 1984; 8: 143-57.
6. Waseem NH, Lane DP. Monoclonal antibody analysis of proliferating cell nuclear antigen (PCNA) structural conversation and the detection of a nucleolar form. J Cell Sci 1990; 96: 121-9.
7. Bolton WE, Mikulka WR, Healy CG, Schmittling RJ, Kenyon NS. Expression of proliferation associated antigen in the cell cycle of synchronized mammalian cells. Cytometry 1992; 13: 117-26.
8. Bravo R, Macdonald-Bravo H. Existence of two population of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites. J Cell Biol 1987; 105: 1546.
9. Dervan PA, Magee HM, Buckley C, Carney DN. Proliferating cell nuclear antigen counts in formalin-fixed paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J Clin Pathol 1992; 97(5 supp1): S21-8.
10. Gerdes J, Schwab U, Lempke H, Stein H. Production of mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
11. Lloyd RV, Wilson BS, Varani J, Gaur PR, Moline S, Makani JG. Immunocytochemical characterization of a monoclonal antibody that recognizes mitosing cells. Am J Pathol 1985; 121: 275-83.
12. Dippold WG, Jay G, DeLeo AB, Khorny G, Old LJ. p-53 Transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Acad Sci USA 1981; 78: 1695-9.
13. Persson H, Hennighausen L, Taub R, De Grado W, Leder P. Antibodies to human C-myconcogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science 1984; 225: 687-93.
14. Pinder SE, Ellis IO. Breast screening pathology. Surgery 1994; 112: 277-8.
15. Ghazizadeh M, Sasaki Y, Araki T, Konishi H, Achara K. Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analyses. Am J Clin Pathol 1997; 107: 451-8.
16. Ramsey JA, From L, Iscoe NA, Kahn HJ. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 1995; 105: 22-6.
17. Shen KL, Harn HJ, Ho LI, Yu CP, Chin SC, Lee WH. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin 11-dUTP nick end labeling. Cancer 1998; 82: 2373-81.
18. Silvestrini R, Daidone MG, Gasparini G. Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 1985; 56: 1982.
19. Mujkanovic N, Granic M, Opric D. Markers of ductal carcinoma in situ. Med Arh 2002; 56: 159-62.
20. Kato T, Kameako S, Kimuna T. C-erb B-2 and PCNA as prognostic indicators of long-term survival in breast cancer. Anticancer Res 2002; 22: 1097-1103.
21. Takashima T, Onoda N, Ishikawa T. Prognostic value of combined analysis of ER status and cellular proliferative activity in breast cancer patients with extensive lymph node metastases. Oncol Rep 2002; 9: 589-94.
22. Horita K, Yamaguchi A, Hirose K. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem 2001; 45: 73-84.